Meanwhile, serious adverse event occurrence has increased from 18.0% (atezolizumab) to 21.0% (tiragolumab plus atezolizumab).55 There are a series of phase 3 clinical trials of anti-TIGIT plus anti-PD-L1 or anti-PD-1 in patients with lung cancer, ESCC, and upper gastrointestinal tract adenocarcinoma.56 This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.